« Return to News | Drug Sponsors

Valeant Pharmaceuticals to acquire Natur Produkt in Russia

Monday, March 26, 2012 10:58 AM

Valeant Pharmaceuticals International has signed a $180 million agreement to acquire Natur Produkt International, a specialty pharmaceutical company in St. Petersburg, Russia.

Natur Produkt will have the potential to receive an additional $5 million in future milestones. The acquisition will give Valeant the Russian company’s over-the-counter brands AntiGrippin, a cough and cold remedy, Anti Angin, Sage and Eucaplyptus, sore throat remedies, and several more.

"Not only is the OTC market very attractive in Russia due to the self-pay element, but it is also one of the fastest growth components of the Russian healthcare system,” stated J. Michael Pearson, chairman and CEO, Valeant. “The addition of this high-growth operation… will bring our pro forma revenues in Russia to approximately $175 million by the end of 2012."

The transaction is expected to close by mid-year 2012, subject to certain closing adjustments and regulatory approvals, and is expected to be immediately accretive.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.